Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors

Inclusion criteria: * Advanced or metastatic malignant disease originating from solid tumors * Adequate recovery from previous therapy or intervention; at least 21 days since major surgery or prior radiation therapy * Measurable or evaluable disease Exclusion criteria: * Women of childbearing potential (WOCBP) who are breastfeeding, pregnant, or unwilling or unable to use acceptable contraception during the study and for at least 12 weeks after the last on-study dose of cetuximab * Men unwilling to use acceptable contraception during the study if engaged in sexual relations with a WOCBP * Symptomatic brain metastasis * History of myocardial infarction 6 months or less prior to study entry, of severe congestive heart failure, of uncontrolled angina, or of uncontrolled arrhythmias * Clinically relevant abnormality on screening electrocardiogram (ECG), preventing an accurate measurement of the QT interval * Congenital long QT syndrome * History of risk factors for ventricular tachycardia or Torsades de pointes or history of fainting, unexplained loss of consciousness, or convulsions * Prolonged QTc interval on screening ECG (greater than 470 msec) using Fridericia's correction formula * Heart rate slower than 50 bpm or faster than 100 bpm at rest during screening ECG measurements * Implantable pacemaker or automatic implantable cardioverter defibrillator * Sustained supine systolic blood pressure higher than 150 mmHg or lower than 90 mmHg or a diastolic blood pressure lower t…